Immunogenicity and safety study of GSK Biologicals' meningococcal vaccine GSK134612 administered in healthy subjects either previously primed with Mencevax ACWY [meningococcal vaccine groups A C Y W-135 polysaccharide] or naive to meningococcal vaccination.

Trial Profile

Immunogenicity and safety study of GSK Biologicals' meningococcal vaccine GSK134612 administered in healthy subjects either previously primed with Mencevax ACWY [meningococcal vaccine groups A C Y W-135 polysaccharide] or naive to meningococcal vaccination.

Completed
Phase of Trial: Phase II

Latest Information Update: 30 Sep 2016

At a glance

  • Drugs Meningococcal vaccine groups A C Y W-135 conjugate (Primary)
  • Indications Meningococcal group A infections; Meningococcal group C infections; Meningococcal group W-135 infections; Meningococcal group Y infections; Meningococcal infections
  • Focus Pharmacodynamics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 02 Feb 2009 Actual patient numbers (272) added as reported by ClinicalTrials.gov.
    • 02 Feb 2009 Actual end date (Dec 2008) added as reported by ClinicalTrials.gov.
    • 02 Feb 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top